Gilead Sciences, Inc. $GILD Shares Sold by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,167 shares of the biopharmaceutical company’s stock after selling 644 shares during the period. Koss Olinger Consulting LLC’s holdings in Gilead Sciences were worth $2,014,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Ashton Thomas Private Wealth LLC raised its position in shares of Gilead Sciences by 4.6% during the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 47,869 shares of the biopharmaceutical company’s stock valued at $5,307,000 after acquiring an additional 2,101 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Gilead Sciences by 2.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,847,975 shares of the biopharmaceutical company’s stock valued at $204,885,000 after acquiring an additional 38,568 shares in the last quarter. Chilton Capital Management LLC raised its position in shares of Gilead Sciences by 58.4% during the 2nd quarter. Chilton Capital Management LLC now owns 372,849 shares of the biopharmaceutical company’s stock valued at $41,338,000 after acquiring an additional 137,531 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Gilead Sciences by 4.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 362,516 shares of the biopharmaceutical company’s stock valued at $40,192,000 after acquiring an additional 16,947 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,500 shares of company stock valued at $7,142,140. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GILD shares. Wolfe Research upped their price target on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Royal Bank Of Canada upped their price target on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group upped their price target on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $120.94 on Monday. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business’s fifty day moving average price is $115.47 and its two-hundred day moving average price is $111.11. The firm has a market capitalization of $150.06 billion, a PE ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period last year, the company earned $2.01 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.